Vimarsana
Biggest News Aggregation in the World

Page 8 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects - Vimarsana News

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’...

Lexicon Elects Diane E. Sullivan to Board of Directors - Vimarsana News

Lexicon Elects Diane E. Sullivan to Board of Directors

THE WOODLANDS, Texas, July 28, 2023 -- Lexicon Pharmaceuticals, Inc. today announced that Diane E. Sullivan has been elected to its Board of Directors. Ms. Sullivan brings extensive...

VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML - Vimarsana News

VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

First and only FLT3 inhibitor approved across three phases of AML treatment based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival Third innovative...

Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure - Vimarsana News

Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of... | June 15, 2023

Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) - Vimarsana News

Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin)

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes ...